Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Merck Sharp & Dohme LLC
Yelena Y Janjigian; Akihito Kawazoe; Yuxian Bai; Jianming Xu; Sara Lonardi; Jean Phillipe Metges; Patricio Yanez; Lucjan S Wyrwicz; Lin Shen; Yuriy Ostapenko; Mehmet Bilici; Hyun Cheol Chung; Kohei Shitara; Shu-Kui Qin; Eric Van Cutsem; Josep Tabernero; Kan Li; Chie-Schin Shih; Pooja Bhagia; Sun Young Rha; KEYNOTE-811 Investigators